MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
2.720
-0.050
-1.81%
After Hours: 2.730 +0.01 +0.37% 19:46 03/06 EST
OPEN
2.720
PREV CLOSE
2.770
HIGH
2.770
LOW
2.640
VOLUME
6.37M
TURNOVER
--
52 WEEK HIGH
4.175
52 WEEK LOW
0.6925
MARKET CAP
650.25M
P/E (TTM)
-5.0765
1D
5D
1M
3M
1Y
5Y
1D
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
HLS THERAPEUTICS ANNOUNCES NILEMDOTM (BEMPEDOIC ACID) IS NOW AVAILABLE IN CANADA FOR THE REDUCTION OF LDL-CHOLESTEROL IN PATIENTS AT RISK OF CARDIOVASCULAR DISEASE
Reuters · 1d ago
Balanced Risk-Reward Keeps Esperion at Hold Amid Complex Corstasis Acquisition and CHF Market Challenges
TipRanks · 2d ago
Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)
TipRanks · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Passage Bio (PASG)
TipRanks · 3d ago
Esperion Therapeutics Falls on Deal to Buy Edema Treatment Maker Corstasis
Dow Jones · 3d ago
Esperion Therapeutics Is Maintained at Buy by Needham
Dow Jones · 3d ago
Esperion Therapeutics Price Target Raised to $5.00/Share From $4.00 by Needham
Dow Jones · 3d ago
More
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.